Literature DB >> 15327895

Adenovirus-based gene therapy during clevudine treatment of woodchucks chronically infected with woodchuck hepatitis virus.

Yuao Zhu1, John M Cullen, Carol E Aldrich, Jeffry Saputelli, Darren Miller, Christoph Seeger, William S Mason, Allison R Jilbert.   

Abstract

Interferon-alpha (IFN-alpha) is a potent suppressor of hepatitis B virus (HBV) replication in the HBV-transgenic mouse, depleting virus replication intermediates from infected hepatocytes via pathways mediated by interferon-gamma (IFN-gamma) and tumor necrosis factor alpha (TNF-alpha). It has also been hypothesized that cytokines induce curing of infected hepatocytes via non-cytolytic pathways during resolution of transient hepadnavirus infections. We have therefore evaluated therapy of chronic woodchuck hepatitis virus (WHV) infections using treatment with the nucleoside analog clevudine [L-FMAU; 1-(2-fluoro-5-methyl-b-L-arabinofuranosyl) uracil] and therapy with adenovirus vectors expressing INF-gamma, TNF-alpha, and beta-galactosidase. Before their use in vivo, expression of IFN-gamma and TNF-alpha from the adenovirus vectors was evaluated in vitro. Conditioned media from adenovirus-infected WC-3 cells was shown to inhibit WHV replication in baculovirus-transduced cells. Adenovirus super-infection of the liver in woodchucks led to declines in the percentage of hepatocytes with detectable core antigen and nucleic acids, and in levels of covalently closed circular DNA (cccDNA) and total WHV DNA, but a major long-term benefit of adenovirus super-infection during clevudine treatment was not demonstrated. Moreover, the effect took at least 2 weeks to develop suggesting that the declines in the percentage of WHV-infected cells, ccc, and total WHV DNA resulted from induction of the adaptive immune response by the adenovirus super-infection, and only indirectly from the expression of cytokines by the vectors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15327895     DOI: 10.1016/j.virol.2004.06.017

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  8 in total

Review 1.  The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection.

Authors:  Stephan Menne; Paul J Cote
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

2.  Clonal expansion of hepatocytes during chronic woodchuck hepatitis virus infection.

Authors:  William S Mason; Allison R Jilbert; Jesse Summers
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-18       Impact factor: 11.205

3.  The amount of hepatocyte turnover that occurred during resolution of transient hepadnavirus infections was lower when virus replication was inhibited with entecavir.

Authors:  William S Mason; Chunxiao Xu; Huey Chi Low; Jeffry Saputelli; Carol E Aldrich; Catherine Scougall; Arend Grosse; Richard Colonno; Sam Litwin; Allison R Jilbert
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

4.  The liver of woodchucks chronically infected with the woodchuck hepatitis virus contains foci of virus core antigen-negative hepatocytes with both altered and normal morphology.

Authors:  Chunxiao Xu; Toshiki Yamamoto; Tianlun Zhou; Carol E Aldrich; Katy Frank; John M Cullen; Allison R Jilbert; William S Mason
Journal:  Virology       Date:  2006-10-31       Impact factor: 3.616

Review 5.  Ideal Cure for Hepatitis B Infection: The Target is in Sight.

Authors:  Shrihari A Anikhindi; Ashish Kumar; Praveen Sharma; Vikas Singla; Naresh Bansal; Anil Arora
Journal:  J Clin Exp Hepatol       Date:  2017-11-07

6.  Therapeutic vaccination in chronic hepatitis B: preclinical studies in the woodchuck.

Authors:  Anna D Kosinska; Ejuan Zhang; Mengji Lu; Michael Roggendorf
Journal:  Hepat Res Treat       Date:  2010-09-07

Review 7.  Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance.

Authors:  Hung-Chih Yang; Jia-Horng Kao
Journal:  Emerg Microbes Infect       Date:  2014-09-17       Impact factor: 7.163

8.  In Situ Liver Expression of HBsAg/CD3-Bispecific Antibodies for HBV Immunotherapy.

Authors:  Robert L Kruse; Thomas Shum; Xavier Legras; Mercedes Barzi; Frank P Pankowicz; Stephen Gottschalk; Karl-Dimiter Bissig
Journal:  Mol Ther Methods Clin Dev       Date:  2017-08-31       Impact factor: 6.698

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.